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Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that
arises from a putative thymic medulla B cell. It constitutes 2–4% of non-Hodgkin lymphomas
and occurs most frequently in young females. PMBCL is characterized by a diffuse
proliferation of medium-to-large B cells associated with sclerosis. Molecular analysis shows
that PMBCL is a distinct entity compared to other types of diffuse large B-cell lymphomas.
PMBCL is characterized by a locally invasive anterior mediastinal bulky mass. The combination
of rituximab with CHOP/CHOP-like regimens followed by mediastinal radiation therapy (RT) is
associated with a 5-year progression-free survival of 75–85%. However, the role of
consolidation RT still remains uncertain. More intensive regimens, such as DA-EPOCH-R
without mediastinal RT, have shown very promising results. The conclusive role of PET-CT
scan requires prospective studies and there is hope that this may allow to de-escalate RT and
accordingly yield reliable prognostic information.
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Primary mediastinal large B-cell lymphoma
(PMBCL) is a unique variant of B-cell lym-
phoma that arises from a putative thymic
medulla B cell. Because of its peculiar epidemio-
logical, morphological and immunophenotypic
characteristics, PMBCL has been identified as a
specific entity recognized by the WHO classifi-
cation of lymphoid malignancies [1,2]. PMBCL
constitutes 2–4% of non-Hodgkin lymphomas
(NHL) [3]. It is more common in young adults
(median age 35–40 years) with a female pre-
dominance, originates in the mediastinum and
is characterized by an aggressive and locally inva-
sive behavior [4,5].
Diagnosis & clinical presentation
The diagnosis of PMBCL is based on the inte-
gration of morphological, immunophenotypic,
genetic and clinical data according to the
WHO classification [2]. The differential diag-
nosis should be primarily made with classical
Hodgkin lymphoma (cHL), mediastinal gray
zone lymphoma (MGZL) and other nodal dif-
fuse large B-cell lymphoma (DLBCL)-NOS
subtypes from which in some cases it cannot
be readily distinguished.
Histopathology & immunophenotype
It is postulated that PMBCL derives from the
small subset of thymic B cells with asteroid
shape located around the Hassall’s corpuscles in
the medullary thymus which share with
PMBCL a CD10-, CD21-, CD23+ pheno-
type [6,7]. The clinical presentation within the
anterior mediastinum and the identification of
normal thymic cells that express the MAL
protein support this hypothesis [8]. PMBCL is
characterized by a diffuse proliferation of
medium-to-large B cells associated with sclerosis
and a degree of compartmentalization [2]. Lym-
phomatous elements show polymorphic nuclei
and a wide rim of cytoplasm that is either clear
or slightly basophilic. Less often, the neoplastic
cells resemble immunoblasts. The fibrotic reac-
tion is easily appreciated in the form of thin
strands of reticulin fibers that surround clusters
of neoplastic cells. In more than half of the
cases, there are prominent collagen bands that
emphasize the compartmentalization, which
may constitute a dominant feature of the micro-
scopic picture [9–11]. In some series, sclerosis has
been defined as a diagnostic criterion, but its
variability in different areas of the same tumor
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makes this an impractical diagnostic requirement with the small
biopsy samples usually available. Not infrequently, Reed-Stern-
berg-like cells may be seen. In such instances, careful immunohis-
tochemical evaluation is warranted to exclude the diagnosis of
cHL. In this regard, it should also be noted that ‘gray zone’ bor-
derline cases combining features of PMBCL and cHL or cases of
composite PMBCL and cHL can rarely be encountered [12].
Regarding immunohistochemical analysis, despite generally lack-
ing surface and cytoplasmic immunoglobulin, PMBCL expresses
B-cell-related antigens such as CD19, CD20, CD22, CD79a,
PAX5 and CD45. CD30 staining is observed in the vast majority
of cases (~80%) although it is weaker and less homogeneous than
in cHL and anaplastic large cell lymphoma [13]. CD15 is occa-
sionally present. Tumor cells are more frequently positive for
BCL2 (55–80%) and CD23 (70%), while BCL6 expression is
variable (45–100%) and CD10 is more often negative (8–
32%) [12–15]. Tumor cells are often MAL positive as a conse-
quence of MAL gene overexpression [8,16,17]. The latter is located
on the long arm of chromosome 2 and encodes a protein thought
to play a role in membrane trafficking and signaling which might
contribute to pathogenesis [18]. PMBCLs usually also express
BOB1, PU1 and OCT2 (FIGURE 1) [13,14].
Differential diagnostic criteria
The main differential diagnoses are with cHL and DLBCL. cHL
can be distinguished from PMBCL by histological features such
as an abundant infiltration with granulocytes and lymphocytes as
well as histiocytes in the former. In addi-
tion, cHL expresses CD15 and less often a
full set of B-cell markers [19]. MAL has
been reported to be specifically expressed
in PMBCL but it is a rather difficult
marker to stain in routine practice. Some
cases with either morphological features of
PMBCL but immunophenotypic features
of cHL or vice versa do not allow a final
diagnosis and are classified as B-cell lym-
phoma unclassifiable, with features inter-
mediate between DLBCL and cHL or
so-called MGZL [12]. These tumors mor-
phologically show cells larger and more
pleomorphic than in the typical cases of
PMBCL. Pleomorphic cells resemble lacu-
nar cells and Hodgkin lymphoma (HL)
cells. A characteristic feature is the broad
spectrum with different areas of the tumor,
some more closely to cHL and others
appear more like DLBCL. On immuno-
phenotipe, analysis of neoplastic cells typi-
cally expresses CD45 but in contrast with
cHL the B-cell program is often preserved
but is aberrantly expressed in concert with
cHL markers such as CD30 and CD15.
CD20 and CD79a are also frequently pos-
itive and may be strongly expressed on the
majority of tumor cells. The transcription factors PAX-5,
OCT2 and BOB1 are also usually expressed (TABLE 1) [14,18].
The differential diagnosis with nodal DLBCL-NOS is not
always easy. The distinct morphological features of PMBCL,
such as clear cell proliferation and sclerosis, may be difficult to
evaluate on small biopsies and there is a lack of well-defined
diagnostic criteria that can be routinely applied. The expression
of CD23 in PMBCL may be useful in that respect [20]. Gene
expression analysis allows for an improved distinction between
PMBCL and DLBCL-NOS but can as yet not be used in the
clinical practice [21–23]. These difficulties are of relevant impact
on evaluation of clinical trials where a mixed series of PMBCL
and DLBCL-NOS might confuse the final results.
Genetic characteristics
PMBCL has a unique gene expression profile signature that is
different from other nodal DLBCL and more closely related to
cHL. The hallmark of the transcriptional signature of PMBCL
is the deregulation of JAK-STAT signaling. The underlying
genetic basis for this observation is the recurrent amplification
involving JAK2 on chromosome band 9p24, which occurs in
50–70% of PMBCL [24,25]. Other molecular mechanisms of
JAK-STAT activation in PMBCL are the disruption of SOCS1
and PTPN1 that physiologically act as negative regulators of
JAK-STAT signaling and mutations of STAT6. Multiple altera-
tions of JAK-STAT signaling genes tend to co-occur in PMBL,
suggesting an additive effect of the signaling pathway hits [26].
CD20 100%
CD30 87%
CD23 70%
CD15 ---
EBV ---
Bcl-6
Bcl-2
80%
IRF4 75%
80%
Ig (ISH) ---
BOB.1/Oct-2/PU.1 80%
MAL protein 70%
CD20
MAL
CD30
Ig
A B
Figure 1. Histopathology and immunohistochemical findings in primary
mediastinal large B-cell lymphoma. (A) Histopathology usually consists of medium to
large cells with clear cytoplasm, evokes fibrosis with compartmentalization and
(B) Immunohistochemistry typically shows the expression of CD30, CD20 and MAL pro-
teins and negativity of surface and cytoplasmic immunoglobulins.
Ig: Immunoglobulin.
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Besides JAK2, the amplified region at 9p24 also includes
JMJD2C, CD274 (alias PDL1) and PDCD1LG2 (alias PDL2).
JAK2 and JMJD2C are coordinately overexpressed in PMBCL
and function in concert to epigenetically modify CD274 and
PDCD1LG2. Amplification and epigenetic modification func-
tion in concert to boost the expression of CD274 and
PDCD1LG2, which encodes inhibitors of T-cell response essen-
tial for the malignant PMBCL clone to escape immune surveil-
lance of the thymus microenvironment [27–29]. Translocations
involving CIITA, a transactivator of MHC class II genes, occur
in approximately 40% of PMBCL and represent a second
mechanism of immune escape of this lymphoma. CIITA trans-
locations invariably fuse the N terminus of CIITA in frame
with a variety of other genes. As a result, one copy of CIITA is
inactivated, and the fusion protein can also act in a dominant-
negative manner to extinguish MHC class II expression,
thereby limiting the ability of the tumor cells to interact with
T cells [30]. JAK inhibitors switching off PDL expression and
downmodulating the canonical JAK-STAT signaling could be
considered as preclinical model for a targeted therapy of
PMBCL [31,32] (FIGURE 2).
Clinical presentation & prognostic factors
PMBCL normally presents with a bulky tumor in the anterior
mediastinum that is rapidly progressive and gives rise to local
compressive symptoms including early dyspnea, cough, dyspha-
gia and compromising the airway or great vessels, producing a
superior vena cava syndrome. Up to one-half of patients have
symptoms and signs of superior vena cava syndrome, thoracic
and neck vein distension, facial edema, conjunctival swelling
and occasionally arm edema. This results in relatively early pre-
sentation so that at diagnosis most patients (around 80%) have
stage I or II disease. The mediastinal tumor is frequently bulky,
being over 10 cm in about 70–80% of patients, infiltrating the
lungs, chest wall, pleura and pericardium [3,33]. Pleural or peri-
cardial effusions are present in one-third of cases [34,35]. Breast
edema is common and hoarseness may reflect recurrent laryn-
geal nerve damage (FIGURE 3).
Despite the local invasiveness, distant spread is infrequent at
the onset and even spread to the supraclavicular nodes is usual
at presentation. Extranodal sites may however be involved, par-
ticularly in cases of disease recurrence, with a propensity for
involvement of the kidneys, adrenal glands, liver, ovaries and
CNS [36–38]. The duration of symptoms is rarely longer than
3 months. Systemic symptoms, mainly fever or weight loss, are
present in less than 20% of cases. Spread to marrow or cere-
brospinal fluid involvement is unusual. Moderate to high LDH
levels are observed in 70–80% of cases [39]. MGZL shows simi-
lar clinical features, but compared to PMBCL it is more com-
mon in young men and more often presents extranodal
Table 1. Comparison of pathological and immunophenotypic features of primary mediastinal large B-cell
lymphoma, diffuse large B-cell lymphoma, nodular sclerosis classical Hodgkin lymphoma and mediastinal
gray zone lymphoma.
Features Primary mediastinal
large B-cell
lymphoma
Diffuse large B-cell
lymphoma
Classical Hodgkin
lymphoma
Mediastinal gray zone
lymphoma
Morphology Sheets of large cells,
clear cells,
noninflammatory
Sheets of large cells
with variable aspects
Lacunar Hodgkin
Reed-Sternberg cells
Inflammatory
polymorphous infiltrate
Sheets of pleomorphic large
cells, Lacunar Hodgkin Reed-
Stenberg cells; sparse
inflammatory infiltrate
Sclerosis 70–100% (alveolar,
fine bands)
Absent 100% (large bands) Focal fibrous bands
CD45 Positive Positive Negative Positive
CD30 Positive weak
(70–80%)
Rare (anaplastic
variant)
Positive Positive
CD15 Negative Negative Positive Positive
CD20 Positive Positive Negative Positive
CD23 Positive Negative Negative Negative
CD79a Positive Positive Usually negative Positive
PAX-5 Positive Positive Weak positive Positive frequently
Immunoglobulin Negative Positive Negative Negative
BOB-1 Positive Positive Negative Positive frequently
OCT-2 Positive Positive Negative Positive frequently
MAL expression 60–70% <10% <20% 30–40%
Primary mediastinal lymphoma Review
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involvement and B symptoms. MGZL showed a significant
poor prognostic outcome when compared to PMBCL (TABLE 2)
[40].
The complete staging workup includes an accurate physical
examination, complete hematological and biochemical examina-
tions, total body computerized tomography (CT) and bone mar-
row biopsy. A diagnostic tissue sample can be obtained by
mediastinoscopy, biopsy of the tumor mass through the supra-
clavicular fossa, anterior mediastinotomy or minithoracotomy. It
is important to consider the anesthetic
risk for patients with critical airways nar-
rowing by anterior mediastinal tumors:
sometimes it may be preferable to obtain
a needle core biopsy by a percutaneous
route under local anesthesia rather than to
obtain a larger biopsy but having a patient
who cannot be extubated following the
procedure because of an airway compro-
mise [41]. PMBCL shows almost universal
avidity for [18F]-2-fluoro-2-deoxyglucose,
making PET (FDG-PET) an effective
means to assess disease extent and to char-
acterize residual masses at the completion
of treatment. The extent of experience
with this technique is however too limited
to permit major changes to therapy based
upon FDG-PET scans, pending the
results of prospective trials. The utility of
the International Prognostic Index (IPI)
in PMBCL is limited by the age distribu-
tion of the disease and its usual confine-
ment to the mediastinum. This is
reflected by the observation that half of
the patients have low IPI scores at presentation [39]. The age-
adjusted IPI has similarly been reported to be of limited predic-
tive value in PMBCL. This may reflect differences between stud-
ies, assigning patients as either stage IV or stage IIE when
contiguous extranodal sites such as the lungs are involved [42–45].
An elevated LDH to more than twice the upper limit of normal,
age over 40 and performance status ‡2 correlated with reduced
survival in a population-based series from British Columbia [44],
while in a large series from the International Extranodal Lym-
phoma Study Group (IELSG), male sex, poor performance sta-
tus and advanced-stage disease were significant negative
predictors [46]. The presence of noncontiguous mediastinal extra-
nodal disease (kidneys, adrenal glands, liver and ovaries) at diag-
nosis and/or early inadequate response to induction therapy,
considered as a response less than partial response (PR), should
be considered as significant prognostic factors for a poor
outcome [43].
Treatment & outcome
The first-line treatment and its outcome are critical in managing
PMBCL. Salvage treatment for recurrence/progression of disease
is of limited efficacy. On the basis of this concept, it is impera-
tive to cure the disease with the first-line treatment. The first
issue to consider is represented by the choice of initial chemo-
therapy: first-generation versus third-generation chemotherapy
regimens and the inclusion of rituximab in the front-line treat-
ment. Other issues include any potential benefit from high-dose
therapy (HDT) in first remission, the role of consolidation
radiotherapy to the mediastinum and the potential role of func-
tional imaging (FDG-PET) to guide treatment choices. It is
however important to strike an appropriate balance between
STAT6
JAK2
Cytokine
receptors
Nuclear
membrane
50–70%
Histon3
Canonical signaling
SOCS1
40%
JAK2 Active chromatin
PDL1
PDL2
PDL1 PDL2
MYC
Noncanonical signaling
50–70%
Proliferation
and survival
PTPN1
40%
30%
Target
genes
P
P
Figure 2. JAK-STAT pathway deregulation and regulation of PDL1 and
PDL2 expression.
PDL: Programmed death ligand.
Figure 3. CT scan from a female patient presenting with
primary mediastinal large B-cell lymphoma. Note the large
anterior mediastinal mass, with areas suggestive of central
necrosis and bilateral breast edema.
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delivery of the highest possible cure fraction and minimization
of long-term morbidity for this young population of patients.
Early studies suggesting that PMBCL were unusually aggres-
sive, with a poorer prognosis with respect to other nodal diffuse
large-cell lymphomas, have been contradicted by more recent
reports. There is a broad agreement that for nodal DLBCL the
standard of care is the R-CHOP regimen. Prior to the intro-
duction of rituximab, some retrospective and prospective series
suggested that superior outcomes in PMBCL might be achieved
with more intensive third-generation regimens. Whereas the
CHOP regimen has been used by American investigators, sev-
eral European centers have suggested that the V/MACOP-B
(etoposide/methotrexate, doxorubicin, cyclophosphamide, vin-
cristine, prednisone, and bleomycin) regimen may be superior
to CHOP [34,45,47–49]. However, the debate is still open because
it is difficult to compare the advantages of the different types
of protocols, and it is also difficult to explain the rather differ-
ent complete response (CR) and survival rates reported by dif-
ferent institutions using similar regimens in Phase II studies.
On the basis of published Phase II data by centers that have
used both first-generation chemotherapy regimens such as
CHOP and other more aggressive third-generation ones such
as V/MACOP-B, the results have clearly favored the latter.
Lazzarino et al. treated 30 patients; the CR rate after CHOP
was 36%, whereas that after MACOP-B was 73% [35]. In an
Italian multicenter study of 106 patients, the 3-year relapse-free
survival (RFS) was 38% in the 47 patients treated with
CHOP, whereas it was 58% in the 62 patients treated with
MACOP-B or VACOP-B [43]. In two Italian prospective stud-
ies, we used the MACOP-B regimen in 50 and 89 patients
and the CR rates were 86 and 88%, respectively, whereas the
5-year RFS rates were 93 and 91%, respectively [48,49]. In addi-
tion, two retrospective studies have reported data regarding the
comparison between CHOP and CHOP-like regimens versus
MACOP-B and MACOP-B-like regimens as induction chemo-
therapy in patients with PMBCL. In the first study,
Todeschini et al. reported the long-term results from a retro-
spective multicenter Italian experience in 138 patients with
PMBCL treated with CHOP (43 patients) or MACOP-
B/VACOP-B (95 patients). The CR rate was 51% in the
CHOP group and 80% in the MACOP-B/VACOP-B group.
The addition of radiation therapy (RT) on mediastinum mass
consolidation improved the outcome regardless of the type of
chemotherapy [45]. In a multinational retrospective study from
the IELSG, which reviewed the outcomes of 426 previously
untreated patients with PMBCL after first-generation (CHOP
and CHOP-like regimens; 105 patients), third-generation
(MACOP-B, VACOP-B; 277 patients) and high-dose chemo-
therapy schedules (high-dose sequential and autologous stem
cells transplantation; 44 patients). In all these groups, the
majority of patients underwent RT after chemotherapy.
Although the CR rate was similar between the third-generation
subgroup and those treated with conventional CHOP/CHOP-
like regimens, the relapse rate at 3 years was significantly lower
in the third-generation group (12 vs 23%; p = 0.02) and the
projected 10 years overall survival (OS) and PFS were superior
at 71 and 67% compared to 44 and 33% (p = 0.0001 and
p = 0.0003), respectively) [46]. These two retrospective studies
suggest the superiority of the third-generation chemotherapy
strategies over the first-generation ones. In addition, they high-
light the role of RT for converting from PR to CR, and proba-
bly also of consolidating the CR (TABLE 3). However, the
following introduction of rituximab in the clinical practice
guidelines has changed this opinion. The British Columbia
Cancer Agency (BCCA) carried out a population-based retro-
spective analysis of 153 patients with PMBCL whose treatment
was determined by era-specific guidelines. The 5-year OS for
the entire cohort was 75%, with a 5-year OS of 87% for those
treated with MACOP-B/VACOP-B, which is significantly
higher than the 71% for patients treated with CHOP
(p = 0.048). In the multivariate analysis for OS, the type of
chemotherapy regimen showed a trend toward improved
Table 2. Comparison of clinical features of primary mediastinal large B-cell lymphoma, diffuse large B-cell
lymphoma, nodular sclerosis classical Hodgkin lymphoma and mediastinal gray zone lymphoma.
Features Primary mediastinal
large B-cell lymphoma
Diffuse large
B-cell lymphoma
Classical Hodgkin
lymphoma
Mediastinal gray
zone lymphoma
Female/male ratio 2:1 1:1 1:1 1:2
Median age (years) 35 55 28 35
Stage I–II 70–80% 30% 55% 70–80%
Mediastinal involvement All 20% 80% 80%
Extranodal sites Uncommon Common Uncommon Uncommon
Bone marrow 2% 10–15% 3% 3%
Elevated LDH 70–80% 50% Rare 70–80%
B symptoms <20% 50% 40% 40%
Bulky disease 70–80% 10–15% 50% 70–80%
Primary mediastinal lymphoma Review
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outcomes but this was not statistically significant. However, in
patients receiving R-CHOP this difference disappeared [44]. It
is generally accepted that the addition of rituximab to chemo-
therapy for PMBCL yields superior results. The MabThera
International Trial (MiNT) compared the outcomes for
824 patients with low-risk DLBCL randomized to receive
CHOP-like chemotherapy with or without rituximab, which
included a subset of 87 patients with low IPI risk PMBCL.
The difference in OS did not reach statistical significance
owing to the small number of PMBCL (3-year OS 78 vs 89%;
p = 0.16), but was of the same order as that seen for the whole
trial (85 vs 93%; p < 0.001) [50]. In a small series from Israel,
the addition of rituximab appeared to improve PFS, particu-
larly in patients receiving CHOP, while there was no difference
in outcome in a comparison between either a third-generation
regimen with rituximab (R-M/VACOP-B) or R-CHOP
(84 and 74%, respectively; p = 0.44) [51]. On the other hand,
in a recent study including all IPI risk patients with PMBCL
treated with conventional R-CHOP showed an unacceptably
high rate of primary refractory disease in 13/63 (21%) with a
5-year PFS and OS of 68 and 79%, respectively. In particular
patients with a high IPI score and advanced extranodal disease
had a significantly worse outcome [52]. In an Italian retrospec-
tive analysis, 45 previously untreated patients with PMBCL
were treated with a combination of a third-generation chemo-
therapy regimen V/MACOP-B concurrent with rituximab and
mediastinal RT. The projected 5-year OS and RFS were
80 and 88%, respectively. In comparison with historical data of
V/MACOP-B without rituximab, we did not find any signifi-
cant difference [53]. Overall, it appears likely that the use of rit-
uximab reduces the distinction between different chemotherapy
regimens and R-CHOP should be considered the most widely
used regimen in PMBCL [54]. However, unlike for other types
of DLBCL in PMBCL, the more intensive weekly regimens
(V/MACOP-B) or a dose-dense CHOP (CHOP-14) combined
with rituximab could improve the quality of clinical response
and PFS over the standard R-CHOP-21. This could be
explained by the more similar biology of PMBCL to HL in
which the increase of dose intensity (BEACOPP/esc) has
improved both OS and PFS. More recently in a single group
Phase II study from the National Cancer Institute, the addition
of rituximab to infusional dose-adjusted etoposide, doxorubicin
and cyclophosphamide with vincristine, prednisone (DA-
EPOCH-R) without radiotherapy in 51 patients with untreated
PMBCL has shown a very favorable outcome with CR in 48/
51 (94%) and a 3-year event-free survival (EFS) and OS of
93 and 97%, respectively. Only three patients had evidence of
disease after DA-EPOCH-R treatment; two had persistent focal
disease, as detected on FDG-PET-CT and one had disease pro-
gression. Two of these patients underwent mediastinal consoli-
dation radiotherapy and one was observed after excisional
biopsy. These results were also confirmed in a retrospective
Table 3. Reported studies on management and outcome of patients with primary mediastinal large B-cell
lymphoma treated in the pre-rituximab era.
Study (year) Patients (N) Regimen CR rate (%) RFS (%) OS (%) Ref.
Todeschini et al. (1990) 21 CHOP (6)
MACOP-B (15)
0
87
90 (5 years) nr [50]
Lazzarino et al. (1993) 30 CHOP
MACOP-B
36
73
72 (3 years) 36 (3 years) [35]
Cazals-Hatem et al.
(1996)
141 M-BACOD
ACVBP
79 61 (3 years) 66 (3 years) [4]
Lazzarino et al. (1997) 106 CHOP (47)
V/MACOP-B (62)
37
58
71 (3 years) 52 (3 years) [43]
Martelli et al. (1998) 37 MACOP-B + IFRT (27)
F-MACHOP + IFRT (10)
88
60
91 (5 years
60 (5 years)
93 (5 years)
70 (5 years)
[47]
Zinzani et al. (1999) 50 MACOP-B + IFRT 86 93 (5 years) 73 (3 years) [49]
Zinzani et al. (2001) 89 MACOP-B + IFRT 88 91 (5 years) 34 (3 years) [48]
Todeschini et al. (2004) 138 CHOP ± IFRT (43)
V/MACOP-B ± IFRT (95)
51
80
39 (5 years)
76 (5 years)
nr
nr
[45]
Zinzani et al. (2002) 426 CHOP ± IFRT (105)
V/MACOP-B ± IFRT (277)
HDS-ASCT (44)
61
79
75
33 (10 years)
67 (10 years)
78 (10 years)
44 (10 years)
71 (10 years)
77 (10 years)
[46]
De Sanctis et al. (2006) 92 MACOP-B + IFRT 87 81 (5 years) 82 (5 years) [58]
Mazzarotto et al. (2007) 53 V/MACOP-B + IFRT 42 87 (5 years) 94 (5 years) [57]
CR: Complete response; nr: Not reported; OS: Overall survival; RFS: Relapse-free survival.
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Stanford cohort where 16 patients with PMBCL treated with
DA-EPOCH-R were 100% alive and event-free over a median
follow-up of 37 months [55]. However, these enthusiastic results
represent a series of patients accrued over more than a decade
at a single institution, and for these reasons need to be vali-
dated in larger multicenter trials (TABLE 4).
Mediastinal consolidation radiotherapy
Irradiation of the mediastinum is one of the most controversial
aspects of the management of PMBCL. It is not attractive to
administer radiation extensively to a group dominated by youn-
ger subjects, who may be put at increased risk of second malig-
nancies, especially breast cancer and accelerated coronary artery
disease. On the other hand, the chances of cure following recur-
rence of PMBCL are relatively poor, so that any approach which
puts patients at increased risk of relapse should be strenuously
avoided. It is clear from the IELSG series that many patients
completing chemotherapy in PR may be converted to CR follow-
ing radiotherapy [46] and that radiotherapy may render inactive
residual mediastinal masses 67gallium or PET-CT positive [49]
resulting in a long-term remission. Mazzarotto et al. reported
that following induction chemotherapy 42% of patients were in
CR, rising to 95% following radiotherapy [56]. Univariate and
multivariate analyses in two retrospective series have suggested
that the use of radiotherapy was correlated with better EFS and
OS [45,46,56,57]. Those who would prefer to avoid irradiation of the
mediastinum can however point to good results in studies that
have used chemotherapy alone [4]. In a BCCA retrospective
study, the introduction of routine radiotherapy to consolidate
response after chemoimmunotherapy was not accompanied by
any improvement in PFS and OS, even for initially bulky dis-
ease [44]. The study from Memorial Sloan-Kettering Cancer Cen-
ter (MSKCC) which used radiotherapy in only 7% of patients
treated with the NHL-15 regimen showed excellent results, with
an OS of 84% at a median follow-up of over 10 years [42]. Simi-
larly, the excellent results that have been recently reported with
DA-EPOCH-R have further strenghtened this argument, with
93% of EFS among 51 patients. Only two of them received
radiotherapy, purporting to negate the need for radiation in this
disease [55]. Given the concerns about the long-term toxicity of
radiation, a randomized study is needed to address its role, espe-
cially now that rituximab is incorporated into the treatment of
PMBCL. For this reason, an international Phase III randomized
trial (IELSG 37) is now ongoing to assess the role of consolida-
tion RT in PMBCL patients with PET-negative mediastinal
masses after standard chemoimmunotherapy. The trial should be
able to demonstrate a noninferior outcome in patients not receiv-
ing consolidation RT [58]. The study may eventually allow to
individualize treatment for each patient by adapting it to the
PET response limiting the indication for additional radiotherapy
only to PET-positive patients with an inadequate response
to chemoimmunotherapy.
Role of PET scan in assessment of response & to guide
therapy choice
The presence of bulky masses at the time of diagnosis, together
with the extensive fibrotic elements of PMBCL, often results in
a residual mediastinal mass being present at the completion of
initial chemoimmunotherapy. It may be difficult to distinguish
inert fibrous tissue from viable residual lymphoma on conven-
tional cross-sectional imaging, and for this reason functional
imaging has been extensively investigated. Functional imaging
studies using PET-CT scans have suggested that it may be possi-
ble to distinguish residual mediastinal masses which contain
active lymphoma from those in which only sclerotic material
remains. PET-CT scans are now widely used as prognostic
Table 4. Reported studies on management and outcome of patients with primary mediastinal large B-cell
lymphoma treated in the post-rituximab era.
Study (year) Patients (N) Regimen CR rate (%) RFS (%) OS (%) Ref.
Savage et al. (2006) 153 MACOP-B (47)
CHOP (67)
R-CHOP (19)
77† 69 (5 years)† 87 (5 years)
71 (5 years)
81 (5 years)
[44]
Zinzani et al. (2009) 45 R-V/MACOP-B + IFRT 62 88 (5 years) 80 (5 years) [54]
Moskowitz et al. (2010) 54 R-CHOP14-ICE 82 78 (3 years) 88 (3 years) [65]
Rieger et al. (2010) 87 CHOP-like (43)
R-CHOP-like (44)
54
80
64 (3 years)
88 (3 years)
78 (3 years)
88 (35 years)
[51]
Vassilakopoulos et al. (2012) 120 R-CHOP (75)
CHOP (45)
90
64
81 (5 years)
48 (5 years)
91 (5 years)
69 (5 years)
[55]
Dunleavy et al. (2013) 51 DA-EPOCH-R 94 93 (3 years) 97 (3 years) [56]
Avigdor et al. (2014) 95 R-VACOP-B/R-CHOP (43)
VACOP/B- CHOP(52)
82 79 (5 years)
58 (5 years)
97 (5 years)
88 (5 years)
[52]
Soumerai et al. (2014) 63 R-CHOP 71 68 (5 years) 79 (5 years) [53]
†CR and RFS for the entire group of patients.
CR: Complete response; OS: Overall survival; RFS: Relapse-free survival.
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indicators [59–61] and are incorporated in the definitions of the
response criteria for DLBCL [62,63]. However, the studies per-
formed to date in PMBCL have not yet fully clarified the role of
PET-CT scans in the definition of complete metabolic response
(CMR) and whether consolidation radiotherapy might be
avoided solely on the basis of a negative PET-CT scan. In a ret-
rospective study of 54 PMBCL patients treated with the
R-CHOP/ICE dose-dense regimen without mediastinal RT, the
MSKCC group reported 3-year OS and PFS of 88 and 78%,
respectively, in patients who were PET negative at the end of
the chemotherapy regimen. An interim PET-CT scan was per-
formed on 51/54 patients, and in 24/51 (47%) of those patients
it was abnormal but did not predict for PFS [64]. In the BCCA
study, 96 PMBCL were treated with R-CHOP. Before 2005,
consolidation RT to the mediastinum was routinely adminis-
tered following R-CHOP, while after 2005 a PET-CT scan was
planned at the end of chemotherapy to guide RT; if the PET
was negative, patients were observed and if the PET was positive,
consolidation RT was given if possible. Of 59 PET scans at the
end of treatment, 35 (59%) were negative (two received RT)
and 24 (41%) were positive (23 received RT). The recurrence
rate among PET-negative patients after R-CHOP managed
without RT was 6/35 (four mediastinal) compared to 4/24 (three
mediastinal) treated with RT. With a median follow-up of more
than 5 years, there was no survival difference between PET-
negative and PET-positive cases, suggesting that at least a small
proportion of PET-negative patients may benefit from consoli-
dation radiotherapy and that a PET-guided RT approach in
R-CHOP-treated PMBCL may reduce the use of RT while
maintaining good outcomes. However, we are also taking in
account that a proportion of patients who were PET negative
and did not receive RT (4/35) relapsed in the mediastinum [65].
This retrospective study from BCCA also confirmed the higher
post-treatment PET-positive rate (41%) in PMBCL than in
other DLBCL, despite good clinical outcomes following
consolidation radiotherapy [65]. Similar
results have been reported in two retro-
spective Italian trials of PMBCL [66]. In
particular, the Zinzani et al. study in
which a series of 74 PMBCL patients
were treated with R-MACOP-B,
51 patients (61%) who were PET positive
received mediastinal RT, while the
remaining 23 (39%) who were PET nega-
tive did not. No significant differences in
5-year EFS (91 vs 90%) were found
between PET-negative and PET-positive
cases [67]. The study from the National
Cancer Institute using DA-EPOCH-R has
further strengthened this argument, with
93% EFS among 51 patients, only two of
whom received radiotherapy [55]. Never-
theless, only a prospective randomized
trial such as the ongoing IELSG 37 trial
will be able to confirm or refute this. To
assess the role of PET-CT after chemoimmunotherapy in
patients with PMBCL, the IELSG started in 2007 a prospective
Phase II study (IELSG 26 study). Among 125 patients prospec-
tively enrolled, 115 were eligible for central review of PET-CT
scans at the completion of standard chemoimmunotherapy using
the Deauville 5-point score; 102 (89%) of these patients also
received a consolidation RT. Fifty-four patients (47%) achieved
a CMR, defined as a completely negative scan or with residual
18-FDG activity below the mediastinal blood pool (MBP)
uptake (score 1–2). In the remaining 61 patients (53%), the
residual uptake was higher than the MBP but below the liver
uptake (score 3) in 27 (23%) and slightly and markedly higher
than the liver uptake (score 4–5) in 34 (30%). CMR after che-
moimmunotherapy predicted a higher 5-year PFS (98 vs 82%;
p = 0.0044) and OS (100 vs 91%; p = 0.0298). Patients with
residual uptake higher than the MBP but below the liver uptake
(score 3) had equally good outcomes, without any recurrence.
Using the liver uptake as cut-off for PET positivity (score 4–5)
discriminated most effectively between high or low risk of fail-
ure, with 5-year PFS of 99 versus 68% (p < 0.0001) and 5-year
OS of 100 versus 83% (p = 0.0003) (FIGURE 4). However, 90% of
patients were projected to be alive and PFS at 5 years, despite
the low CMR rate (47%) and a very low positive-predict value
of 18% after chemoimmunotherapy albeit after the use of con-
solidation radiotherapy in 102 cases [68]. Similarly, the series of
patients treated with the DA-EPOCH-R regimen showed a
50% PET positivity, defined by FDG uptake greater than the
MBP at the completion of chemoimmunotherapy, but only
3/18 had progressive disease without the use of consolidation
radiotherapy. All cases that recurred had a standardized uptake
value of at least 5, and the authors therefore suggested that
radiotherapy might reasonably be omitted for nearly all patients
treated with this regimen [55]. In the IELSG 26 study, we have
also measured, in 103 of 125 patients, the standardized uptake
value, metabolic tumor volume and total lesions glycolysis
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Figure 4. Progression-free survival curve in primary mediastinal large B-cell
lymphoma according to PET response defined at 3–4 weeks after
chemoimmunotherapy using liver uptake as a cut-off point (Deauville score 4–5)
in the IELSG 26 study. Median follow-up time was 2.9 years (95% CI: 2.7–3.2).
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(TLG) at the baseline PET-CT scans
according to the standard protocol. At
5 years, the OS was 100% for patients
with low TLG compared to 80% for
those with high TLG (p = 0.0001), while
the PFS was 97 versus 64%, respectively
(p < 0.0001). The value of TLG on base-
line PET scan outcome should be consid-
ered in future studies as a powerful
predictor in PMBCL [69].
These data indicate that PET-CT scan
in PMBCL has an excellent negative pre-
dictive value but limited positive predic-
tive value due to high frequency of
positive scans. This false positive rate in
particular requires further definition
before modifying planned therapy based
upon FDG-PET evaluation alone in
PMBCL, although deescalation of ther-
apy based upon the finding of a negative
FDG-PET scan is entering clinical prac-
tice. Several patients with persistent meta-
bolically active masses underwent
biopsies, which showed necrosis but no
lymphoma. It has been suggested that an inflammatory
response produced by the addition of rituximab to chemother-
apy or a thymic rebound, which is particularly relevant given
the location of the disease and their generally young age, may
cause increased FDG uptake and thus reduce the positive-
predict value and specificity [70]. A longer interval might result
in a lower rate of false positive scans, but at the potential risk
of missing the opportunity for a curative RT in some patients
with persistent disease (FIGURE 5).
High-dose therapy & ASCT as intensification of first
remission
The low frequency of marrow involvement and the relatively
young age of the PMBCL patient population are the basis
for consideration of HDT and peripheral blood progenitor
rescue to consolidate first remission. In the GELTAMO
series, 35 patients in first CR, but considered at ‘high risk’ of
relapse, underwent HDT with various preparative regimens.
At 4 years, the OS and PFS were 84 and 81%, respec-
tively [71]. In the Memorial Sloan-Kettering experience, HDT
with progenitor cell rescue at first remission was not superior
to dose-dense sequential therapy [42]. Based upon the results
achieved with third-generation regimens and the likely bene-
fit from the addition of rituximab, there is no good evidence
to recommend a HDT to consolidate first CR, even in poor-
risk patients. The results obtained with R-CHOP/MACOP-B
with/without mediastinal RT or with a more intensive che-
moimmunotherapy regimen such as DA-EPOCH-R appear
comparable with the reports of HDT-ASCT as consolidation
first-line therapy. The exception to this may be for those
patients whose lymphoma progress or obtain an inadequate
response during first-line therapy and with a positive post
chemoimmunotherapy PET-CT scan. However, these groups
of patients have a very poor outlook and it is appropriate in
this setting to test chemosensitivity to a second-line regimen
prior to myeloablative treatment and consolidate the response
with involved field RT.
Treatment of recurrent disease
The probability of recurrence after successful initial therapy for
PMBCL appears to be lower than that of DLBCL in general,
although this may reflect the earlier stage at presentation, the
younger age or possibly the biology of the disease. Patients
with PMBCL who achieve a response lasting longer than
18 months after diagnosis are likely to be cured. Treatment
failure usually occurs either during initial treatment or within
the first 6 to 12 months after completion of treatment [37,43,49].
Most patients with PMBCL will initially respond to therapy
with a rapid decrease in the tumor mass, but rapid disease pro-
gression during treatment cycles is not uncommon. PMBCL
can either recur locally in the mediastinum or can spread to
parenchymal organs, especially the kidneys and spleen. Bone
marrow and CNS involvement are rare even at the time of
recurrence [36]. Second-line treatment strategies are similar to
those used for DLBCL, attempting reinduction with non-cross-
resistant agents, followed by consolidation with HDT-ASCT in
those with a chemosensitive disease. In general, the outcomes
of these patients have been disappointing [72,73]. The broad use
of rituximab in first-line therapy has made recurrence less fre-
quent but harder to manage successfully [74].
A B
Basal PET-CT
Figure 5. Basal and post-chemoimmunotherapy PET-CT scan of two young
female patients with primary mediastinal large B-cell lymphoma treated with
rituximab chemotherapy (R-MACOP-B). (A) At the completion of chemoimmunother-
apy, the patient presented a score of 2 according the Deauville 5-point score. (B) At the
completion of chemoimmunotherapy, the patient presented a score of 4 according to
the Deauville 5-point score.
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Novel approaches & biological agents
JAK-STAT pathway deregulation is the hallmark of PMBCL
and cHL and positively regulates the expression of PDL1 and
PDL2. PDL1 and PDL2 overexpression are instrumental in
PMBCL to survive in the thymic microenvironment. JAK inhib-
itors switch off PDL expression and downmodulate the canoni-
cal JAK-STAT signaling [28–30]. The results of these studies have
shed light on the biology of PMBCL, and some of the dysregu-
lated molecular mechanisms described above will become a pre-
clinical model for a future targeted therapy. Preclinical studies
show that selective inhibition of JAK2 with fedratinib reduces
phosphorylation of JAK2 and other proteins from the STAT
family in cHL and PMBCL cell lines. It also inhibits the expres-
sion of PDL1. In murine models, the inhibition of
JAK2 decreased significantly tumor growth and prolonged sur-
vival, which was correlated with reduced STAT3 expression [31].
PDL1 has already become a target in clinical trials in different
cancers with response rates in the range of 20–25% and it seems
to be also a natural targeted therapy for lymphomas overexpress-
ing PDL [75]. Several agents targeting the PD-1 pathway have
been studied in hematological malignancies. In particular, pidili-
zumab (humanized IgG-1 recombinant monoclonal antibody)
and nivolumab (fully humanized IgG-4 monoclonal antibody)
directed at the PD-1 receptor have shown a significant activity
in Phase I–Ib trials for relapsed/refractory non-Hodgkin lym-
phoma [76]. A Phase II trial is currently registered on clinical-
trials.gov for nivolumab in patients with relapsed/refractory
DLBCL/PMBCL who failed ASCT or two prior standard regi-
mens and are transplant ineligible [77].
Expert commentary
PMBCL is a distinct clinical and biological entity characterized
by aggressive and locally invasive behavior that can lead to a
respiratory clinical emergency. We recommend an accurate his-
tological diagnosis to exclude other mediastinal lymphomas
(cHL, MGZL) followed by a rapid start of chemotherapy. The
combination of rituximab with CHOP/CHOP-like (R-CHOP)
or with V/MACOP-B or dose-dense CHOP (CHOP14) regi-
mens should be considered as the current standard treatment.
The role of rituximab combined with more intensive chemo-
therapy regimens (DA-EPOCH-R) needs to be further con-
firmed on a larger series of patients. A post-treatment PET-CT
response evaluation should be performed not before 5–6 weeks
from the last infusion of chemotherapy to minimize the inci-
dence of false positive scans. Patients with residual and meta-
bolically active masses should be considered as partial
responders and treated with mediastinal RT. Patients with a
negative post chemotherapy PET-CT scan should be consid-
ered as metabolic CR. In this group of patients, the role of
consolidative RT is still a matter of debate. The results of the
ongoing comparative randomized trial will allow to assess if a
consolidative RT could be spared in patients with a negative
PET-CT scan. Considering the results achieved with conven-
tional rituximab combination regimens or with more intensive
regimens such as DA-EPOCH-R, there is no good evidence to
recommend a HDT-ASCT to consolidate first CR, even in
poor-risk patients. An intensification therapy with HDT-ASCT
should be reserved only for patients who obtain an inadequate
response with an elevated FDG uptake at the post chemoim-
munotherapy PET-CT scan. Salvage treatment strategies of
relapsed/resistant patients are similar to those utilized for
DLBCL, attempting reinductions with non-cross-resistant
agents, followed by consolidation with HDT-ASCT in patients
with chemosensitive disease.
Five-year view
In the next 5 years, we could hope to solve the following clini-
cal open questions in the management of PMBCL: Conclu-
sively define the efficacy and safety of more intensive
chemotherapy regimens, such as DA-EPOCH-R, in a larger
multicenter series of patients. Clarify if consolidative mediasti-
nal RT could be spared in selected patients and if PET-CT
scans can drive this selection. An international Phase III ran-
domized trial (IELSG 37) is now ongoing to assess the role of
consolidation RT in patients with post chemoimmunotherapy
PET-negative mediastinal masses. Evaluate the role and impact
of new biological drugs targeting selective pathways (JAK-
STAT, PDL1, PDL2).
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Key issues
. Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct clinical and biological entity from other types of diffuse large B-cell
lymphoma (DLBCL).
. PMBCL has a better outcome compared to other nodal DLBCL probably related to younger age and localized disease.
. Rituximab combination with CHOP/CHOP-like regimens could nullify the differences with more intensive third-generation regimens (e.g.,
V/MACOP-B).
. R-CHOP/CHOP-like and MACOP-B/VACOP-B therapies with consolidation mediastinal RT in selected patients should be considered as the
standard treatment.
. DA-EPOCH-R without mediastinal radiation therapy has shown very promising results, but this therapeutic advance needs to be
confirmed in further prospective trials.
. The rate of post treatment PET positivity is higher than in other DLBCL, using the mediastinal blood pool cut-point; however, post-
treatment negative PET-computerized tomography is significantly associated with a better survival.
. The liver uptake according to Deauville visual analysis may represent a more appropriate cut-point to identify patients with increased
risk of relapse.
. The real role of consolidative mediastinal radiotherapy needs to be better assessed in prospective comparative studies.
. Recent investigations have brought new insight into the molecular mechanisms that contribute to the malignant phenotype of PMBCL
and this may lead to a future development of targeted therapies.
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